Chemed Corporation
Get $10 bonus on your first $100 deposit for CHE
Get $10 bonus on your first $100 deposit for CHE
Chemed Corporation (CHE) Stock Competitors & Peer Comparison
See (CHE) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Care Facilities Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CHE | $387.62 | +0.46% | 5.3B | 21.15 | $18.33 | +0.59% |
| HCA | $497.42 | +0.39% | 111.2B | 17.55 | $28.34 | +0.59% |
| THC | $192.99 | -1.15% | 17B | 12.45 | $15.49 | N/A |
| FMS | $23.72 | +0.38% | 13.7B | 11.79 | $2.01 | +3.33% |
| SOLV | $67.41 | +2.46% | 11.7B | 7.60 | $8.88 | N/A |
| UHS | $183.20 | +1.34% | 11.6B | 7.93 | $23.10 | +0.44% |
| ENSG | $200.30 | +0.64% | 11.6B | 34.36 | $5.83 | +0.13% |
| EHC | $107.56 | +0.29% | 10.8B | 19.38 | $5.55 | +0.69% |
| DVA | $151.56 | +1.01% | 10.1B | 15.94 | $9.51 | N/A |
| OSH | $39.00 | +0.08% | 9.5B | -17.65 | -$2.21 | N/A |
Stock Comparison
CHE vs HCA Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, HCA has a market cap of 111.2B. Regarding current trading prices, CHE is priced at $387.62, while HCA trades at $497.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas HCA's P/E ratio is 17.55. In terms of profitability, CHE's ROE is +0.24%, compared to HCA's ROE of -1.41%. Regarding short-term risk, CHE is less volatile compared to HCA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check HCA's competition here
CHE vs THC Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, THC has a market cap of 17B. Regarding current trading prices, CHE is priced at $387.62, while THC trades at $192.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas THC's P/E ratio is 12.45. In terms of profitability, CHE's ROE is +0.24%, compared to THC's ROE of +0.35%. Regarding short-term risk, CHE is less volatile compared to THC. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check THC's competition here
CHE vs FMS Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, FMS has a market cap of 13.7B. Regarding current trading prices, CHE is priced at $387.62, while FMS trades at $23.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas FMS's P/E ratio is 11.79. In terms of profitability, CHE's ROE is +0.24%, compared to FMS's ROE of +0.07%. Regarding short-term risk, CHE is more volatile compared to FMS. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check FMS's competition here
CHE vs SOLV Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, SOLV has a market cap of 11.7B. Regarding current trading prices, CHE is priced at $387.62, while SOLV trades at $67.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas SOLV's P/E ratio is 7.60. In terms of profitability, CHE's ROE is +0.24%, compared to SOLV's ROE of +0.37%. Regarding short-term risk, CHE is less volatile compared to SOLV. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SOLV's competition here
CHE vs UHS Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, UHS has a market cap of 11.6B. Regarding current trading prices, CHE is priced at $387.62, while UHS trades at $183.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas UHS's P/E ratio is 7.93. In terms of profitability, CHE's ROE is +0.24%, compared to UHS's ROE of +0.21%. Regarding short-term risk, CHE is less volatile compared to UHS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check UHS's competition here
CHE vs ENSG Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, ENSG has a market cap of 11.6B. Regarding current trading prices, CHE is priced at $387.62, while ENSG trades at $200.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas ENSG's P/E ratio is 34.36. In terms of profitability, CHE's ROE is +0.24%, compared to ENSG's ROE of +0.17%. Regarding short-term risk, CHE is more volatile compared to ENSG. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check ENSG's competition here
CHE vs EHC Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, EHC has a market cap of 10.8B. Regarding current trading prices, CHE is priced at $387.62, while EHC trades at $107.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas EHC's P/E ratio is 19.38. In terms of profitability, CHE's ROE is +0.24%, compared to EHC's ROE of +0.24%. Regarding short-term risk, CHE is more volatile compared to EHC. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check EHC's competition here
CHE vs DVA Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, DVA has a market cap of 10.1B. Regarding current trading prices, CHE is priced at $387.62, while DVA trades at $151.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas DVA's P/E ratio is 15.94. In terms of profitability, CHE's ROE is +0.24%, compared to DVA's ROE of -1.61%. Regarding short-term risk, CHE is less volatile compared to DVA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check DVA's competition here
CHE vs OSH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, OSH has a market cap of 9.5B. Regarding current trading prices, CHE is priced at $387.62, while OSH trades at $39.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas OSH's P/E ratio is -17.65. In terms of profitability, CHE's ROE is +0.24%, compared to OSH's ROE of +4.64%. Regarding short-term risk, CHE is more volatile compared to OSH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check OSH's competition here
CHE vs LHCG Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, LHCG has a market cap of 5.3B. Regarding current trading prices, CHE is priced at $387.62, while LHCG trades at $169.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas LHCG's P/E ratio is 82.83. In terms of profitability, CHE's ROE is +0.24%, compared to LHCG's ROE of +0.04%. Regarding short-term risk, CHE is more volatile compared to LHCG. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check LHCG's competition here
CHE vs OPCH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, OPCH has a market cap of 4.5B. Regarding current trading prices, CHE is priced at $387.62, while OPCH trades at $28.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas OPCH's P/E ratio is 22.78. In terms of profitability, CHE's ROE is +0.24%, compared to OPCH's ROE of +0.15%. Regarding short-term risk, CHE is less volatile compared to OPCH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check OPCH's competition here
CHE vs MMED Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, MMED has a market cap of 4B. Regarding current trading prices, CHE is priced at $387.62, while MMED trades at $14.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas MMED's P/E ratio is -15.31. In terms of profitability, CHE's ROE is +0.24%, compared to MMED's ROE of -0.07%. Regarding short-term risk, CHE is less volatile compared to MMED. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check MMED's competition here
CHE vs AMED Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AMED has a market cap of 3.3B. Regarding current trading prices, CHE is priced at $387.62, while AMED trades at $100.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AMED's P/E ratio is 39.30. In terms of profitability, CHE's ROE is +0.24%, compared to AMED's ROE of +0.09%. Regarding short-term risk, CHE is more volatile compared to AMED. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check AMED's competition here
CHE vs BKD Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, BKD has a market cap of 3.2B. Regarding current trading prices, CHE is priced at $387.62, while BKD trades at $13.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas BKD's P/E ratio is -12.15. In terms of profitability, CHE's ROE is +0.24%, compared to BKD's ROE of -5.24%. Regarding short-term risk, CHE is less volatile compared to BKD. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check BKD's competition here
CHE vs NHC Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, NHC has a market cap of 2.6B. Regarding current trading prices, CHE is priced at $387.62, while NHC trades at $169.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas NHC's P/E ratio is 22.11. In terms of profitability, CHE's ROE is +0.24%, compared to NHC's ROE of +0.12%. Regarding short-term risk, CHE is less volatile compared to NHC. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check NHC's competition here
CHE vs LFST Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, LFST has a market cap of 2.5B. Regarding current trading prices, CHE is priced at $387.62, while LFST trades at $6.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas LFST's P/E ratio is 323.00. In terms of profitability, CHE's ROE is +0.24%, compared to LFST's ROE of +0.01%. Regarding short-term risk, CHE is more volatile compared to LFST. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check LFST's competition here
CHE vs ACHC Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, ACHC has a market cap of 2.4B. Regarding current trading prices, CHE is priced at $387.62, while ACHC trades at $26.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas ACHC's P/E ratio is -2.18. In terms of profitability, CHE's ROE is +0.24%, compared to ACHC's ROE of -0.39%. Regarding short-term risk, CHE is less volatile compared to ACHC. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ACHC's competition here
CHE vs SEM Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, SEM has a market cap of 2B. Regarding current trading prices, CHE is priced at $387.62, while SEM trades at $16.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas SEM's P/E ratio is 14.13. In terms of profitability, CHE's ROE is +0.24%, compared to SEM's ROE of +0.09%. Regarding short-term risk, CHE is more volatile compared to SEM. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check SEM's competition here
CHE vs AMEH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AMEH has a market cap of 1.8B. Regarding current trading prices, CHE is priced at $387.62, while AMEH trades at $40.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AMEH's P/E ratio is 39.25. In terms of profitability, CHE's ROE is +0.24%, compared to AMEH's ROE of +0.04%. Regarding short-term risk, CHE is less volatile compared to AMEH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AMEH's competition here
CHE vs MD Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, MD has a market cap of 1.8B. Regarding current trading prices, CHE is priced at $387.62, while MD trades at $21.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas MD's P/E ratio is 11.24. In terms of profitability, CHE's ROE is +0.24%, compared to MD's ROE of +0.20%. Regarding short-term risk, CHE is less volatile compared to MD. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check MD's competition here
CHE vs ADUS Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, ADUS has a market cap of 1.8B. Regarding current trading prices, CHE is priced at $387.62, while ADUS trades at $95.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas ADUS's P/E ratio is 18.22. In terms of profitability, CHE's ROE is +0.24%, compared to ADUS's ROE of +0.09%. Regarding short-term risk, CHE is less volatile compared to ADUS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ADUS's competition here
CHE vs SGRY Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, SGRY has a market cap of 1.7B. Regarding current trading prices, CHE is priced at $387.62, while SGRY trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas SGRY's P/E ratio is -21.46. In terms of profitability, CHE's ROE is +0.24%, compared to SGRY's ROE of -0.04%. Regarding short-term risk, CHE is less volatile compared to SGRY. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SGRY's competition here
CHE vs ASTH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, ASTH has a market cap of 1.4B. Regarding current trading prices, CHE is priced at $387.62, while ASTH trades at $28.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas ASTH's P/E ratio is 62.78. In terms of profitability, CHE's ROE is +0.24%, compared to ASTH's ROE of +0.03%. Regarding short-term risk, CHE is less volatile compared to ASTH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ASTH's competition here
CHE vs AVAH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AVAH has a market cap of 1.4B. Regarding current trading prices, CHE is priced at $387.62, while AVAH trades at $6.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AVAH's P/E ratio is 6.12. In terms of profitability, CHE's ROE is +0.24%, compared to AVAH's ROE of +9.53%. Regarding short-term risk, CHE is less volatile compared to AVAH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AVAH's competition here
CHE vs HCSG Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, HCSG has a market cap of 1.4B. Regarding current trading prices, CHE is priced at $387.62, while HCSG trades at $19.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas HCSG's P/E ratio is 23.69. In terms of profitability, CHE's ROE is +0.24%, compared to HCSG's ROE of +0.12%. Regarding short-term risk, CHE is less volatile compared to HCSG. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check HCSG's competition here
CHE vs ARDT Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, ARDT has a market cap of 1.3B. Regarding current trading prices, CHE is priced at $387.62, while ARDT trades at $9.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas ARDT's P/E ratio is 9.66. In terms of profitability, CHE's ROE is +0.24%, compared to ARDT's ROE of +0.10%. Regarding short-term risk, CHE is less volatile compared to ARDT. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ARDT's competition here
CHE vs BKDT Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, BKDT has a market cap of 1.2B. Regarding current trading prices, CHE is priced at $387.62, while BKDT trades at $77.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas BKDT's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to BKDT's ROE of -5.24%. Regarding short-term risk, CHE is more volatile compared to BKDT. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check BKDT's competition here
CHE vs USPH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, USPH has a market cap of 1.2B. Regarding current trading prices, CHE is priced at $387.62, while USPH trades at $78.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas USPH's P/E ratio is 55.13. In terms of profitability, CHE's ROE is +0.24%, compared to USPH's ROE of +0.03%. Regarding short-term risk, CHE is less volatile compared to USPH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check USPH's competition here
CHE vs INNV Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, INNV has a market cap of 1.1B. Regarding current trading prices, CHE is priced at $387.62, while INNV trades at $8.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas INNV's P/E ratio is 162.80. In terms of profitability, CHE's ROE is +0.24%, compared to INNV's ROE of -0.02%. Regarding short-term risk, CHE is less volatile compared to INNV. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check INNV's competition here
CHE vs PNTG Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, PNTG has a market cap of 1.1B. Regarding current trading prices, CHE is priced at $387.62, while PNTG trades at $31.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas PNTG's P/E ratio is 37.26. In terms of profitability, CHE's ROE is +0.24%, compared to PNTG's ROE of +0.09%. Regarding short-term risk, CHE is less volatile compared to PNTG. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check PNTG's competition here
CHE vs TALK Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, TALK has a market cap of 865.5M. Regarding current trading prices, CHE is priced at $387.62, while TALK trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas TALK's P/E ratio is 129.50. In terms of profitability, CHE's ROE is +0.24%, compared to TALK's ROE of +0.07%. Regarding short-term risk, CHE is more volatile compared to TALK. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TALK's competition here
CHE vs FSHCX Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, FSHCX has a market cap of 852.6M. Regarding current trading prices, CHE is priced at $387.62, while FSHCX trades at $98.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas FSHCX's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to FSHCX's ROE of N/A. Regarding short-term risk, CHE is more volatile compared to FSHCX. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check FSHCX's competition here
CHE vs AMN Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AMN has a market cap of 718.3M. Regarding current trading prices, CHE is priced at $387.62, while AMN trades at $18.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AMN's P/E ratio is -7.50. In terms of profitability, CHE's ROE is +0.24%, compared to AMN's ROE of -0.15%. Regarding short-term risk, CHE is less volatile compared to AMN. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AMN's competition here
CHE vs EHAB Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, EHAB has a market cap of 708.9M. Regarding current trading prices, CHE is priced at $387.62, while EHAB trades at $13.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas EHAB's P/E ratio is -155.28. In terms of profitability, CHE's ROE is +0.24%, compared to EHAB's ROE of -0.01%. Regarding short-term risk, CHE is more volatile compared to EHAB. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check EHAB's competition here
CHE vs SNDA Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, SNDA has a market cap of 599.6M. Regarding current trading prices, CHE is priced at $387.62, while SNDA trades at $33.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas SNDA's P/E ratio is -7.86. In terms of profitability, CHE's ROE is +0.24%, compared to SNDA's ROE of -0.81%. Regarding short-term risk, CHE is less volatile compared to SNDA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SNDA's competition here
CHE vs CMPS Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, CMPS has a market cap of 554.4M. Regarding current trading prices, CHE is priced at $387.62, while CMPS trades at $5.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas CMPS's P/E ratio is -1.87. In terms of profitability, CHE's ROE is +0.24%, compared to CMPS's ROE of -3.36%. Regarding short-term risk, CHE is less volatile compared to CMPS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CMPS's competition here
CHE vs MCTA Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, MCTA has a market cap of 445.6M. Regarding current trading prices, CHE is priced at $387.62, while MCTA trades at $29.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas MCTA's P/E ratio is 419.36. In terms of profitability, CHE's ROE is +0.24%, compared to MCTA's ROE of -2.33%. Regarding short-term risk, CHE is more volatile compared to MCTA. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check MCTA's competition here
CHE vs CYH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, CYH has a market cap of 424.2M. Regarding current trading prices, CHE is priced at $387.62, while CYH trades at $3.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas CYH's P/E ratio is 0.81. In terms of profitability, CHE's ROE is +0.24%, compared to CYH's ROE of -0.32%. Regarding short-term risk, CHE is less volatile compared to CYH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CYH's competition here
CHE vs AUNA Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AUNA has a market cap of 423.4M. Regarding current trading prices, CHE is priced at $387.62, while AUNA trades at $5.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AUNA's P/E ratio is 15.46. In terms of profitability, CHE's ROE is +0.24%, compared to AUNA's ROE of +0.06%. Regarding short-term risk, CHE is less volatile compared to AUNA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AUNA's competition here
CHE vs AGL Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AGL has a market cap of 358.4M. Regarding current trading prices, CHE is priced at $387.62, while AGL trades at $21.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AGL's P/E ratio is -0.88. In terms of profitability, CHE's ROE is +0.24%, compared to AGL's ROE of -1.17%. Regarding short-term risk, CHE is less volatile compared to AGL. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AGL's competition here
CHE vs TOI Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, TOI has a market cap of 326.2M. Regarding current trading prices, CHE is priced at $387.62, while TOI trades at $3.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas TOI's P/E ratio is -6.11. In terms of profitability, CHE's ROE is +0.24%, compared to TOI's ROE of +7.60%. Regarding short-term risk, CHE is less volatile compared to TOI. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TOI's competition here
CHE vs AONC Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AONC has a market cap of 321.4M. Regarding current trading prices, CHE is priced at $387.62, while AONC trades at $10.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AONC's P/E ratio is -12.35. In terms of profitability, CHE's ROE is +0.24%, compared to AONC's ROE of +0.06%. Regarding short-term risk, CHE is less volatile compared to AONC. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AONC's competition here
CHE vs CCRN Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, CCRN has a market cap of 314.5M. Regarding current trading prices, CHE is priced at $387.62, while CCRN trades at $9.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas CCRN's P/E ratio is -3.32. In terms of profitability, CHE's ROE is +0.24%, compared to CCRN's ROE of -0.24%. Regarding short-term risk, CHE is less volatile compared to CCRN. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CCRN's competition here
CHE vs CSU Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, CSU has a market cap of 223.7M. Regarding current trading prices, CHE is priced at $387.62, while CSU trades at $33.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas CSU's P/E ratio is 0.67. In terms of profitability, CHE's ROE is +0.24%, compared to CSU's ROE of -2.10%. Regarding short-term risk, CHE is less volatile compared to CSU. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CSU's competition here
CHE vs AIRS Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AIRS has a market cap of 189.8M. Regarding current trading prices, CHE is priced at $387.62, while AIRS trades at $2.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AIRS's P/E ratio is -14.16. In terms of profitability, CHE's ROE is +0.24%, compared to AIRS's ROE of -0.14%. Regarding short-term risk, CHE is less volatile compared to AIRS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AIRS's competition here
CHE vs JYNT Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, JYNT has a market cap of 127M. Regarding current trading prices, CHE is priced at $387.62, while JYNT trades at $8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas JYNT's P/E ratio is -443.50. In terms of profitability, CHE's ROE is +0.24%, compared to JYNT's ROE of +0.14%. Regarding short-term risk, CHE is less volatile compared to JYNT. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check JYNT's competition here
CHE vs NAKAW Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, NAKAW has a market cap of 116.4M. Regarding current trading prices, CHE is priced at $387.62, while NAKAW trades at $15.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas NAKAW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to NAKAW's ROE of -0.21%. Regarding short-term risk, CHE is less volatile compared to NAKAW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check NAKAW's competition here
CHE vs FVE Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, FVE has a market cap of 98.4M. Regarding current trading prices, CHE is priced at $387.62, while FVE trades at $2.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas FVE's P/E ratio is -5.64. In terms of profitability, CHE's ROE is +0.24%, compared to FVE's ROE of -0.15%. Regarding short-term risk, CHE is less volatile compared to FVE. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check FVE's competition here
CHE vs KDLYW Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, KDLYW has a market cap of 96.5M. Regarding current trading prices, CHE is priced at $387.62, while KDLYW trades at $18.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas KDLYW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to KDLYW's ROE of -0.21%. Regarding short-term risk, CHE is less volatile compared to KDLYW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check KDLYW's competition here
CHE vs BTMD Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, BTMD has a market cap of 79M. Regarding current trading prices, CHE is priced at $387.62, while BTMD trades at $1.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas BTMD's P/E ratio is 2.42. In terms of profitability, CHE's ROE is +0.24%, compared to BTMD's ROE of -0.35%. Regarding short-term risk, CHE is less volatile compared to BTMD. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check BTMD's competition here
CHE vs DCGO Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, DCGO has a market cap of 57.3M. Regarding current trading prices, CHE is priced at $387.62, while DCGO trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas DCGO's P/E ratio is -0.30. In terms of profitability, CHE's ROE is +0.24%, compared to DCGO's ROE of -0.71%. Regarding short-term risk, CHE is less volatile compared to DCGO. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check DCGO's competition here
CHE vs ALR Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, ALR has a market cap of 44.2M. Regarding current trading prices, CHE is priced at $387.62, while ALR trades at $1.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas ALR's P/E ratio is -1.11. In terms of profitability, CHE's ROE is +0.24%, compared to ALR's ROE of -0.15%. Regarding short-term risk, CHE is more volatile compared to ALR. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check ALR's competition here
CHE vs IMAC Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, IMAC has a market cap of 33.1M. Regarding current trading prices, CHE is priced at $387.62, while IMAC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas IMAC's P/E ratio is -2.27. In terms of profitability, CHE's ROE is +0.24%, compared to IMAC's ROE of +1183.61%. Regarding short-term risk, CHE is less volatile compared to IMAC. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check IMAC's competition here
CHE vs CCEL Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, CCEL has a market cap of 29M. Regarding current trading prices, CHE is priced at $387.62, while CCEL trades at $3.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas CCEL's P/E ratio is -12.00. In terms of profitability, CHE's ROE is +0.24%, compared to CCEL's ROE of +0.15%. Regarding short-term risk, CHE is less volatile compared to CCEL. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CCEL's competition here
CHE vs CANO-WT Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, CANO-WT has a market cap of 19.3M. Regarding current trading prices, CHE is priced at $387.62, while CANO-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas CANO-WT's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to CANO-WT's ROE of -1.49%. Regarding short-term risk, CHE is less volatile compared to CANO-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CANO-WT's competition here
CHE vs AIH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AIH has a market cap of 15.9M. Regarding current trading prices, CHE is priced at $387.62, while AIH trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AIH's P/E ratio is -2.78. In terms of profitability, CHE's ROE is +0.24%, compared to AIH's ROE of +1.16%. Regarding short-term risk, CHE is less volatile compared to AIH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AIH's competition here
CHE vs CANO Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, CANO has a market cap of 12.4M. Regarding current trading prices, CHE is priced at $387.62, while CANO trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas CANO's P/E ratio is -0.01. In terms of profitability, CHE's ROE is +0.24%, compared to CANO's ROE of -1.49%. Regarding short-term risk, CHE is less volatile compared to CANO. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CANO's competition here
CHE vs FTRP Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, FTRP has a market cap of 9.8M. Regarding current trading prices, CHE is priced at $387.62, while FTRP trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas FTRP's P/E ratio is -1.22. In terms of profitability, CHE's ROE is +0.24%, compared to FTRP's ROE of -0.62%. Regarding short-term risk, CHE is less volatile compared to FTRP. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check FTRP's competition here
CHE vs AMS Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AMS has a market cap of 8.8M. Regarding current trading prices, CHE is priced at $387.62, while AMS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AMS's P/E ratio is -5.83. In terms of profitability, CHE's ROE is +0.24%, compared to AMS's ROE of -0.06%. Regarding short-term risk, CHE is less volatile compared to AMS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AMS's competition here
CHE vs PIII Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, PIII has a market cap of 8.1M. Regarding current trading prices, CHE is priced at $387.62, while PIII trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas PIII's P/E ratio is -0.06. In terms of profitability, CHE's ROE is +0.24%, compared to PIII's ROE of +8.94%. Regarding short-term risk, CHE is less volatile compared to PIII. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check PIII's competition here
CHE vs SYRA Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, SYRA has a market cap of 6.6M. Regarding current trading prices, CHE is priced at $387.62, while SYRA trades at $0.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas SYRA's P/E ratio is -7.25. In terms of profitability, CHE's ROE is +0.24%, compared to SYRA's ROE of -0.39%. Regarding short-term risk, CHE is less volatile compared to SYRA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SYRA's competition here
CHE vs MODV Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, MODV has a market cap of 6.2M. Regarding current trading prices, CHE is priced at $387.62, while MODV trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas MODV's P/E ratio is -0.03. In terms of profitability, CHE's ROE is +0.24%, compared to MODV's ROE of +1.84%. Regarding short-term risk, CHE is more volatile compared to MODV. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check MODV's competition here
CHE vs GBNH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, GBNH has a market cap of 5.5M. Regarding current trading prices, CHE is priced at $387.62, while GBNH trades at $0.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas GBNH's P/E ratio is -0.06. In terms of profitability, CHE's ROE is +0.24%, compared to GBNH's ROE of +15.74%. Regarding short-term risk, CHE is less volatile compared to GBNH. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check GBNH's competition here
CHE vs RHE-PA Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, RHE-PA has a market cap of 5.2M. Regarding current trading prices, CHE is priced at $387.62, while RHE-PA trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas RHE-PA's P/E ratio is -0.09. In terms of profitability, CHE's ROE is +0.24%, compared to RHE-PA's ROE of -9.49%. Regarding short-term risk, CHE is less volatile compared to RHE-PA. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check RHE-PA's competition here
CHE vs RHE Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, RHE has a market cap of 5.2M. Regarding current trading prices, CHE is priced at $387.62, while RHE trades at $2.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas RHE's P/E ratio is -1.79. In terms of profitability, CHE's ROE is +0.24%, compared to RHE's ROE of -0.00%. Regarding short-term risk, CHE is less volatile compared to RHE. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check RHE's competition here
CHE vs TOIIW Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, TOIIW has a market cap of 4.8M. Regarding current trading prices, CHE is priced at $387.62, while TOIIW trades at $0.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas TOIIW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to TOIIW's ROE of +7.60%. Regarding short-term risk, CHE is less volatile compared to TOIIW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TOIIW's competition here
CHE vs ATIP Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, ATIP has a market cap of 3M. Regarding current trading prices, CHE is priced at $387.62, while ATIP trades at $0.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas ATIP's P/E ratio is -0.03. In terms of profitability, CHE's ROE is +0.24%, compared to ATIP's ROE of +2.05%. Regarding short-term risk, CHE is less volatile compared to ATIP. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ATIP's competition here
CHE vs IMACW Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, IMACW has a market cap of 1.7M. Regarding current trading prices, CHE is priced at $387.62, while IMACW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas IMACW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to IMACW's ROE of +1.05%. Regarding short-term risk, CHE is less volatile compared to IMACW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check IMACW's competition here
CHE vs MNDR Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, MNDR has a market cap of 749.3K. Regarding current trading prices, CHE is priced at $387.62, while MNDR trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas MNDR's P/E ratio is -0.35. In terms of profitability, CHE's ROE is +0.24%, compared to MNDR's ROE of -0.46%. Regarding short-term risk, CHE is less volatile compared to MNDR. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check MNDR's competition here
CHE vs CCM Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, CCM has a market cap of 565.7K. Regarding current trading prices, CHE is priced at $387.62, while CCM trades at $3.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas CCM's P/E ratio is -0.71. In terms of profitability, CHE's ROE is +0.24%, compared to CCM's ROE of +0.04%. Regarding short-term risk, CHE is less volatile compared to CCM. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check CCM's competition here
CHE vs TALKW Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, TALKW has a market cap of 284K. Regarding current trading prices, CHE is priced at $387.62, while TALKW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas TALKW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to TALKW's ROE of +0.07%. Regarding short-term risk, CHE is less volatile compared to TALKW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TALKW's competition here
CHE vs BACK Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, BACK has a market cap of 208.2K. Regarding current trading prices, CHE is priced at $387.62, while BACK trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas BACK's P/E ratio is -0.02. In terms of profitability, CHE's ROE is +0.24%, compared to BACK's ROE of +1.05%. Regarding short-term risk, CHE is more volatile compared to BACK. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check BACK's competition here
CHE vs NVOS Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, NVOS has a market cap of 69.1K. Regarding current trading prices, CHE is priced at $387.62, while NVOS trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas NVOS's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to NVOS's ROE of -0.81%. Regarding short-term risk, CHE is less volatile compared to NVOS. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check NVOS's competition here
CHE vs NIVFW Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, NIVFW has a market cap of 30.2K. Regarding current trading prices, CHE is priced at $387.62, while NIVFW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas NIVFW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to NIVFW's ROE of +0.33%. Regarding short-term risk, CHE is less volatile compared to NIVFW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check NIVFW's competition here
CHE vs PIIIW Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, PIIIW has a market cap of 14.4K. Regarding current trading prices, CHE is priced at $387.62, while PIIIW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas PIIIW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to PIIIW's ROE of +8.94%. Regarding short-term risk, CHE is less volatile compared to PIIIW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check PIIIW's competition here
CHE vs IONM Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, IONM has a market cap of 1.6K. Regarding current trading prices, CHE is priced at $387.62, while IONM trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas IONM's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to IONM's ROE of +5.28%. Regarding short-term risk, CHE is more volatile compared to IONM. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check IONM's competition here
CHE vs NFH Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, NFH has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while NFH trades at $11.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas NFH's P/E ratio is -19.75. In terms of profitability, CHE's ROE is +0.24%, compared to NFH's ROE of -0.06%. Regarding short-term risk, CHE is more volatile compared to NFH. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check NFH's competition here
CHE vs AFAM Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, AFAM has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while AFAM trades at $56.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas AFAM's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to AFAM's ROE of +0.06%. Regarding short-term risk, CHE is less volatile compared to AFAM. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check AFAM's competition here
CHE vs SLHGP Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, SLHGP has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while SLHGP trades at $12.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas SLHGP's P/E ratio is -30.38. In terms of profitability, CHE's ROE is +0.24%, compared to SLHGP's ROE of -0.71%. Regarding short-term risk, CHE is more volatile compared to SLHGP. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check SLHGP's competition here
CHE vs TVTY Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, TVTY has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while TVTY trades at $32.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas TVTY's P/E ratio is 19.06. In terms of profitability, CHE's ROE is +0.24%, compared to TVTY's ROE of +1.75%. Regarding short-term risk, CHE is more volatile compared to TVTY. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TVTY's competition here
CHE vs SLHG Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, SLHG has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while SLHG trades at $0.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas SLHG's P/E ratio is -1.48. In terms of profitability, CHE's ROE is +0.24%, compared to SLHG's ROE of N/A. Regarding short-term risk, CHE is less volatile compared to SLHG. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check SLHG's competition here
CHE vs ATIP-WT Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, ATIP-WT has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while ATIP-WT trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas ATIP-WT's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to ATIP-WT's ROE of +2.05%. Regarding short-term risk, CHE is less volatile compared to ATIP-WT. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check ATIP-WT's competition here
CHE vs TLMD Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, TLMD has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while TLMD trades at $3.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas TLMD's P/E ratio is -1.60. In terms of profitability, CHE's ROE is +0.24%, compared to TLMD's ROE of -0.46%. Regarding short-term risk, CHE is more volatile compared to TLMD. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check TLMD's competition here
CHE vs DVCR Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, DVCR has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while DVCR trades at $10.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas DVCR's P/E ratio is 28.34. In terms of profitability, CHE's ROE is +0.24%, compared to DVCR's ROE of -0.15%. Regarding short-term risk, CHE is more volatile compared to DVCR. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check DVCR's competition here
CHE vs DCGOW Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, DCGOW has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while DCGOW trades at $1.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas DCGOW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to DCGOW's ROE of -0.71%. Regarding short-term risk, CHE is less volatile compared to DCGOW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check DCGOW's competition here
CHE vs HNGR Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, HNGR has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while HNGR trades at $18.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas HNGR's P/E ratio is 19.71. In terms of profitability, CHE's ROE is +0.24%, compared to HNGR's ROE of +0.52%. Regarding short-term risk, CHE is more volatile compared to HNGR. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check HNGR's competition here
CHE vs KND Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, KND has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while KND trades at $9.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas KND's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to KND's ROE of -0.53%. Regarding short-term risk, CHE is more volatile compared to KND. This indicates potentially higher risk in terms of short-term price fluctuations for CHE.Check KND's competition here
CHE vs TLMDW Comparison April 2026
CHE plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHE stands at 5.3B. In comparison, TLMDW has a market cap of 0. Regarding current trading prices, CHE is priced at $387.62, while TLMDW trades at $0.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHE currently has a P/E ratio of 21.15, whereas TLMDW's P/E ratio is N/A. In terms of profitability, CHE's ROE is +0.24%, compared to TLMDW's ROE of -0.46%. Regarding short-term risk, CHE is less volatile compared to TLMDW. This indicates potentially lower risk in terms of short-term price fluctuations for CHE.Check TLMDW's competition here